Solara Active Pharma Sciences Ltd - 541540 - Statement Of Deviation And Variation For Funds Raised Under Rights Issue For The Quarter Ended March 31, 2026.
Solara Active Pharma Sciences announced no deviation in the utilization of Rs. 309.79 crore funds raised through its Rights Issue for the quarter ended March 31, 2026. The Audit Committee reviewed and approved the statement, confirming Rs. 233.61 crore was utilized.
May 15 2026 14:05:00
Solara Active Pharma Sciences Ltd - 541540 - Intimation In Relation To The Rights Issue
Solara Active Pharma Sciences received Rs.129.94 crore from the second and final call on its rights equity shares. This conversion affects 1.15 crore partly paid shares to fully paid status, strengthening the company's capital structure.
May 15 2026 14:05:00
Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Solara Active Pharma Sciences reported strong Q4 FY26 results with a PAT of Rs.9.6 cr, marking a turnaround to profitability and achieving its highest revenue, gross margin, and EBITDA in eight quarters. The board is also evaluating strategic options for its Ibuprofen business.
May 15 2026 13:05:00
Solara Active Pharma Sciences Ltd - 541540 - Board Meeting Outcome for Board Meeting Outcome For Audited Financial Results For The Year Ended March 31, 2026 And Unaudited Financial Results For The Quarter Ended March 31, 2026.
Solara Active Pharma Sciences board approved Q4 FY26 consolidated net profit of ₹9.60 cr and FY26 consolidated net loss of ₹7.41 cr. The company reported accumulated losses of ₹319.33 cr and net current liabilities exceeding net current assets by ₹35.81 cr, with the board approving results on a going concern basis.
May 15 2026 13:05:00
Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Solara Active Pharma Sciences has announced an investor conference call on May 15, 2026, at 3:00 PM IST to discuss its audited financial results for Q4 FY26. This call will provide an opportunity for analysts and investors to engage with management regarding the company's performance.
May 11 2026 16:05:00
Solara Active Pharma Sciences Ltd - 541540 - Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements), Regulations, 2015 ('Listing Regulations')
Solara Active Pharma Sciences will hold a board meeting on May 15, 2026. The agenda includes considering and approving the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
May 08 2026 21:05:00
Solara Active Pharma Sciences Ltd - 541540 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Solara Active Pharma Sciences successfully closed the US FDA inspection for its Puducherry manufacturing facility. The inspection was classified as Voluntary Action Indicated (VAI), ensuring continued cGMP compliance for the Ibuprofen plant.
Apr 28 2026 17:04:00
Solara Active Pharma Sciences Limited
Solara Active Pharma Sciences announced the successful closure of its Puducherry facility's US FDA inspection, which was classified as 'Voluntary Action Indicated (VAI)'. This outcome demonstrates the company's commitment to quality and regulatory compliance for its Ibuprofen manufacturing unit.
Apr 28 2026 17:04:00
Read More